| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5703462 | Archivos de la Sociedad Española de Oftalmología | 2017 | 4 Pages |
Abstract
The patient had a good response to bevacizumab treatment. In fact, there was a reduction in the macular oedema measured by optical coherence tomography (OCT) scan, as well as an improvement in best corrected visual acuity. There was no recurrence of macular oedema, and visual acuity remained stable after 3-years follow-up.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
J.L. Sánchez-Vicente, A. Muñoz-Morales, M.P. Galván-Carrasco, A. Castilla-Lázpita, C. Vital-Berral, A. Alfaro-Juárez, T. Rueda-Rueda,